Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I

• Tipo: Outra Publicação em Revista Científica Internacional
• Data: 2019

Autores

Vieira, R (Autor) Outra; Souto, SB (Autor) Outra; Sanchez Lopez, E (Autor) Outra; Machado, AL (Autor) Outra; Severino, P (Autor) Outra; Jose, S (Autor) Outra; Santini, A (Autor) Outra; Fortuna, A (Autor) Outra; Garcia, ML (Autor) Outra; Silva, AM (Autor) Outra; Souto, EB (Autor) Outra

Revista

Título: Pharmaceuticals

Vol. 12

Página Final: 152

ISSN: 1424-8247

Editora: MDPI

Indexação

ISI Web of Knowledge - 46 Citações

Scopus - 51 Citações

Classificação Científica

CORDIS: Ciências da Saúde

Outras Informações

ID Authenticus: P-00R-6T0

DOI: 10.3390/ph12040152

Abstract (EN): Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 31